Based on SDG 3 “Ensure healthy lives and promote well-being for all at all ages” the investable sub-goals are:
3.1 Reduce the global maternal mortality ratio
3.2 End preventable deaths of newborns and children under 5 years of age
Investible entities that:
- provide access to maternal care, diagnostics, medicines or treatment relating to maternal disorders (such as high blood pressure, blood-poisoning or infections during pregnancy, bleeding after childbirth)
- provide health care to prevent and manage preterm births
- provide health care for ill and small newborn babies, including management of severe infections
- provide access to vaccines and/or treatment of, in particular, diarrhea and lower respiratory diseases
(such as pneumonia) - provide access to solutions for nutritional deficiencies
3.3 Communicable diseases - End the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases
3.4 Non-communicable diseases – reduce by one third premature mortality from non-communicable diseases and promote mental health and well-being
Communicable and non-communicable diseases
Investible entities that:
- provide access to prevention (incl. vaccines), diagnosis, treatment, medicine and breakthrough innovation for communicable diseases in particular AIDS, tuberculosis, malaria, neglected diseases, hepatitis, water borne diseases
- provide diagnostics, medicine and treatment for non-communicable diseases relating to neoplasms (cancer), cardiovascular diseases, diabetes, neurological disorders, chronic respiratory diseases, cirrhosis and other chronic liver diseases, digestive diseases, urogenital, blood and endocrine diseases, and musculoskeletal disorders
- provide increased access to generic medicine
Mental and Substance use disorders
Providers of diagnostics, medicine and treatment for mental and substance use disorders such as depression, anxiety and substance abuse
Well-being
Providers of products and services that substantially improve the quality of life of patients and the elderly, incl. non-invasive diagnostics and treatment, prostheses, hearing devices
3.7 Ensure universal access to sexual and reproductive health-care services, including for family planning, information and education
Investible entities that:
- provide access to sexual and reproductive health-care services (family planning, education)
- provide contraceptives
3.8 Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all
3.9 Research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines
Healthcare services
Investible entities that:
- provide affordable access to quality essential health-care services (e.g. public hospitals, affordable private clinics)
- produce medical equipment or provide services for more immediate and more accurate diagnoses and treatment
- produce equipment or software (incl. IT) for more efficient health care delivery systems
- provide personal protective devices and equipment (e.g. gloves)
- provide key preventive health care services (incl. sports and sports-related products and services)
- provide clinical nutrition and/or highly specialized diets for medical purposes
X Not luxury private healthcare and wellness facilities
Investible entities that:
- provide transport services (e.g. ambulance) or specialise in healthcare related real estate
- provide employment services for health care personnel
- provide consulting services to the sector that are intended to improve health care services (excluding administrative services).
R&D of vaccines and medicines
Investible entities that:
- provide R&D services and facilities
- provide access to affordable essential medicines and vaccines
X Not luxury private healthcare and wellness facilities
!Providers of care, diagnostics, treatment or medicine that increase prices to a level much higher than is considered reasonable or fair
!Pharma pricing practices and interference with government healthcare policy can be controversial
!Healthcare/pharma companies must be assessed for the alignment between company strategy and access to affordable health care
!Some pharma companies reformulate existing patents leads to no added benefit other than the extension of patent rights
The SDGs and SDG sub-goals have been translated from an investor perspective into the SDI taxonomy of product categories that are considered solutions contributing to the SDGs. The full SDI Taxonomy can be found here. When evaluating a company, the starting point is the classification of its products and services within the SDI product categories. The size of the positive contribution is calculated from the associated revenues (sales).
